In the present study, our aims were: (1) to determine the basal levels of serum LAMP-2 in patients with PBC; (2) to evaluate whether the baseline serum LAMP-2 could serve as a predictor of biochemical response to UDCA; (3) to determine the predictive potency of serum LAMP-2 within the first year of UDCA treatment; (4) to evaluate whether a decline of serum LAMP-2 could prospectively distinguish patients with unsatisfactory biochemical response. The gene discussed is LAMP2; the disease is primary biliary cholangitis.